/f/125658/3386x1417/951de003e4/hfa-acronym-name-rgb.png)
The effect of intravenous ferric-carboxymaltose on cardiac reverse remodeling following cardiac resynchronization therapy - The IRON CRT trial.
Event: Heart Failure 2021
Topic: Pharmacotherapy
Session: Late-Breaking Trials 1
The detrimental effect of right atrial pacing on left atrial function and clinical outcome in cardiac resynchronization therapy.
Event: Heart Failure 2019
Topic: Cardiac Resynchronisation Therapy (CRT)
Session: Rapid Fire 5 - Non-pharmacological treatments: beyond conventional
The importance of optimal dosing of ferric-carboxymaltose to treat iron deficiency
Event: Heart Failure 2019
Topic: Comorbidities
Session: Rapid Fire 4 - Chronic heart failure - Pharmacology
Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in HFrEF.
Event: Heart Failure 2019
Topic: Pharmacotherapy
Session: Moderated Poster Session - Chronic heart failure
Urinary sodium profiling in chronic heart failure to detect the development of acute decompensated heart failure.
Event: Heart Failure 2019
Topic: Pathophysiology
Session: Chronic Heart Failure – Pathophysiology and Mechanisms
The acute and chronic effects of cardiac resynchronization therapy on exercise induced pulmonary hypertension and right ventricular-arterial coupling
Event: EuroEcho-Imaging 2018
Topic: Stress Echocardiography
Session: Clinical practice and stress echo in 2018
The optimal plasma volume status in heart failure in relation to clinical outcome
Event: Heart Failure 2018
Topic: Pathophysiology
Session: Patient management - From oral treatment to transplant
The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction.
Event: Heart Failure 2018
Topic: Pharmacotherapy
Session: Chronic Heart Failure – Treatment
Prevalence of underlying gastro-intestinal malignancies in iron deficient heart failure.
Event: Heart Failure 2018
Topic: Comorbidities
Session: Chronic Heart Failure - Clinical
Effects of intravenous home Dobutamine in palliative end-stage heart failure on quality of life, heart failure hospitalization and cost-expenditure.
Event: Heart Failure 2018
Topic: Treatment, Other
Session: Chronic Heart Failure – Treatment
ESC 365 is supported by
